New class of Drugs for Brain Inflammation?

[Guest guest]

Inflammation in brain inhibited by new class of potential drugs

http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/3349

( this is just part of the article)

The compounds block signals from EP2, one of the four receptors for

prostaglandin E2, which is a hormone involved in processes such as fever,

childbirth, digestion and blood pressure regulation. Chemicals that could

selectively block EP2 were not previously available. In animals, the EP2

blockers could markedly reduce the injury to the brain induced after a prolonged

seizure, the researchers showed.

The results were published online this week in the Proceedings of the National

Academy of Sciences Early Edition.

" EP2 is involved in many disease processes where inflammation is showing up in

the nervous system, such as epilepsy, stroke and neurodegenerative diseases, "

says senior author Ray Dingledine, PhD, chairman of Emory's Department of

Pharmacology. " Anywhere that inflammation is playing a role via EP2, this class

of compounds could be useful. Outside the brain, EP2 blockers could find uses in

other diseases with a prominent inflammatory component such as cancer and

inflammatory bowel disease. "

[Guest guest]

How about finding ways to do away with the sources of inflammation in these areas (i.e., the brain and the bowel), in the first place, whatever they may be? Then, these new classes of drugs may not be needed. Wouldn't that be wonderful? The avenue of seeking out preventive measures seems to be little travelled these days, sadly. Aasa To: EOHarm Sent: Saturday, March 31, 2012 6:03:03 PM Subject: New class of Drugs for Brain Inflammation?

Inflammation in brain inhibited by new class of potential drugs

http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/3349

( this is just part of the article)

The compounds block signals from EP2, one of the four receptors for prostaglandin E2, which is a hormone involved in processes such as fever, childbirth, digestion and blood pressure regulation. Chemicals that could selectively block EP2 were not previously available. In animals, the EP2 blockers could markedly reduce the injury to the brain induced after a prolonged seizure, the researchers showed.

The results were published online this week in the Proceedings of the National Academy of Sciences Early Edition.

"EP2 is involved in many disease processes where inflammation is showing up in the nervous system, such as epilepsy, stroke and neurodegenerative diseases," says senior author Ray Dingledine, PhD, chairman of Emory's Department of Pharmacology. "Anywhere that inflammation is playing a role via EP2, this class of compounds could be useful. Outside the brain, EP2 blockers could find uses in other diseases with a prominent inflammatory component such as cancer and inflammatory bowel disease."